J Gynecol Oncol.  2019 Mar;30(2):e31. 10.3802/jgo.2019.30.e31.

Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline

Affiliations
  • 1Department of Obstetrics and Gynecology, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea. jklee38@gmail.com
  • 2Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, Korea.
  • 3Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
  • 4Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
  • 5Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea.
  • 6Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
  • 7Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Yangsan, Korea.
  • 8Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 9Department of Obstetrics and Gynecology, Asan Medical center, University of Ulsan College of Medicine, Seoul, Korea.
  • 10Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • 11Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea.
  • 12Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea.

Abstract

In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine.

Keyword

Papillomavirus Vaccines; Practice Guidelines; Female; Male
Full Text Links
  • JGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr